πŸ‡ΊπŸ‡Έ FDA
Patent

US 11357817

Immunoproteasome inhibitor

granted A61KA61K38/06A61P

Quick answer

US patent 11357817 (Immunoproteasome inhibitor) held by The Regents of the University of California expires Mon Jun 09 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Regents of the University of California
Grant date
Tue Jun 14 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jun 09 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
7
CPC classes
A61K, A61K38/06, A61P, A61P33/06